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Background. Immune reconstitution inflammatory syndrome (IRIS) in human immunodeficiency virus (HIV)–infected
persons beginning antiretroviral therapy (ART) has been incompletely characterized for herpes simplex virus type 2 (HSV-2).
Methods. We evaluated genital ulcer disease (GUD) and HSV-2–associated GUD at quarterly visits or when spontaneously
reported at monthly visits in 3381 HIV/HSV-2–coinfected individuals in a placebo-controlled trial of suppressive acyclovir therapy
to prevent HIV transmission, 349 of whom initiated ART during the study. Incidence was calculated for months before and after
ART initiation, and incidence rate ratios (IRRs) were calculated.
Results. GUD incidence increased from 15.0 episodes per 100 person-years before ART to 26.9 episodes per 100 person-years in
the first full quarter after ART initiation (IRR, 1.83; P = .03), and the incidence of HSV-2–associated GUD increased from 8.1 to 19.0
episodes per 100 person-years (IRR, 2.20; P = .02). Subsequently, the incidence of GUD was similar to that before ART, although the
numbers were small. Persons receiving suppressive acyclovir had fewer GUD episodes, but the IRR after beginning ART was similar
in the acyclovir and placebo groups.
Conclusions. Initiation of ART in HIV/HSV-2–coinfected persons is associated with a transient increase in GUD and HSV-2
GUD. Acyclovir reduces the incidence of GUD but does not prevent an increase in GUD incidence during the first quarter following
initiation of ART.
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Immune reconstitution inflammatory syndrome (IRIS) was
recognized soon after the first potent antiretroviral regimens
were introduced [1, 2]. Among the first pathogens associated
with IRIS was cytomegalovirus (CMV), manifested as “immune
recovery vitritis” in patients who started combination antiretro-
viral therapy (ART) after recovery from CMV retinitis [3, 4].
Since then, most opportunistic pathogens have been associated
with an IRIS syndrome.
Coinfection with herpes simplex virus type 2 (HSV-2)
and human immunodeficiency virus type 1 (HIV) is common,
owing in part to shared risk factors for infection. A variety of
mechanisms (eg, disruption of mucosal barriers, recruitment
of activated immune cells to genital tissue, and immunosup-
pression) allow each virus to facilitate the acquisition and trans-
mission of the other, creating a viral synergy that helps to main-
tain both pathogens in the human population [5–9]. Because of
this well-established interaction, it is logical to speculate that
treatment of infection due to one of these viruses might influ-
ence the natural history of the other. This viral synergy led to
evaluations of acyclovir as an agent to reduce HIV risk, but ran-
domized, placebo-controlled trials of suppression of HSV-2
with acyclovir did not reduce HIV transmission [10] or acqui-
sition [11, 12]. Similarly, studies have been conducted to deter-
mine the effect of antiretroviral therapy on HSV-2 recurrences.
While some studies suggest chronic ART has little or no impact
on HSV-2 shedding or recurrences [13–15], others have report-
ed that genital herpes recurrences may increase with immune
reconstitution following initiation of ART [16–19]. A recent
study showed both an increase in clinical recurrences and an in-
crease in HSV-2 shedding from the genital tract of persons ini-
tiating ART [20]. To strengthen this evidence in a larger
population and with data on the cause of incident genital ulcers,
we examined the incidence of genital ulcer disease (GUD) and
HSV-2–associated GUD in the presence or absence of acyclovir
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among HIV/HSV-2–coinfected persons who initiated ART
during a randomized, placebo-controlled study of suppressive
acyclovir therapy.
PARTICIPANTS AND METHODS
Participants
All of the individuals in this report were enrolled in the Partners
in Prevention HSV/HIV Transmission Study [10, 21]. Briefly,
this study was a multicenter, randomized, placebo-controlled
trial that examined the ability of acyclovir (400 mg twice
daily) given to an HSV-2/HIV-coinfected individual to prevent
transmission of HIV to their heterosexual partner who was not
infected with HIV at enrollment. The study was conducted be-
tween November 2004 and April 2007 at 14 sites in 7 countries
in Eastern and Southern Africa. The HIV-infected partner had
a CD4+ T-cell count of >250 cells/µL at enrollment and was not
receiving ART. If the HIV-infected partner met local guidelines
for antiretroviral treatment during the 2-year study period, they
were referred for treatment, but they were permitted to remain
in the study. The study randomized 3408 couples, among which
3381 HIV-infected partners were confirmed as coinfected with
HIV/HSV-2 and were eligible for this analysis; follow-up data
were available for 3324. HIV-infected participants were seen
monthly for up to 24 months for study drug refills, adherence
counseling, and transmission risk reduction counseling. At
quarterly visits, interviews were conducted to obtain informa-
tion on symptoms of GUD and on ART initiation in the last
3 months. Participants underwent a genital examination at
each quarterly visit and at any visit if the participant reported
the presence of a genital ulcer. If a genital ulcer was present,
the lesion was swabbed and subsequently tested for HSV-2 by
polymerase chain reaction (PCR) analysis [22, 23]; samples with
≥150 copies/mL in swab eluate were considered positive [24].
Episodic treatment (acyclovir 800 mg twice daily for 5 days)
was provided to treat recurrent episodes of genital herpes le-
sions, based on clinical appearance. CD4+ T cells were counted
at enrollment and every 6 months thereafter during the study.
All participants provided written informed consent, using doc-
uments approved by local ethics committees, the University of
Washington Institutional Review Board (the coordinating cen-
ter), and US partner institutions.
Statistical Analysis
The primary outcome for this analysis was the number of GUD
episodes observed in a calendar quarter. The primary exposure
was ART use by HIV-infected participants, analyzed as a time-
dependent variable and categorized as (1) prior to initiation of
ART, (2) in the first full quarter after initiating ART, or (3) >1
full quarter after initiating ART; the quarter in which ART ini-
tiation was reported was excluded from the primary analysis, as
it could not be classified as entirely before or after ART initia-
tion. After starting ART, participants were conservatively
assumed to be continuing treatment, and adherence to therapy
was not measured. Participants who never started ART during
the study contributed to the analysis with quarters categorized
as “prior to initiation of ART.” An alternative analysis was per-
formed using only data from individuals who eventually started
ART for the “prior to initiation of ART” calculations. Incidence
rate ratios (IRRs) for the effect of initiating ART on the frequen-
cy of GUD were estimated using negative binomial regression
with generalized estimating equations, to account for correla-
tion in multiple outcomes assessed on the same participant
over time. IRRs were estimated for each randomization group
in the clinical trial (ie, acyclovir or placebo) and overall. IRRs
were adjusted for sex, duration of study participation, CD4+
T-cell count as a time-dependent covariate, and randomization
group. The secondary outcome of HSV-2–positive GUD was
analyzed in the same manner. Episodes of GUD for which
swabs were either not collected or not suitable for PCR testing
were conservatively treated as negative for HSV-2; a sensitivity
analysis treated them as missing. Additionally, we examined the
incidence of GUD before and after ART initiation in a subset of
individuals who responded to ART, defined as an increase in
CD4+ T-cell count by at least 50 cells/µL or as a viral load de-
crease of at least 2 log10 following ART initiation. Data were an-
alyzed with SAS, version 9.3).
RESULTS
The baseline characteristics of the study population divided by
study arm and ART initiation are shown in Table 1. About two
thirds of the study participants were women, and the overall
median CD4+ T-cell count was 462 cells/mm3 at enrollment.
Participants who started ART during study follow-up had a
lower median baseline CD4+ T-cell count (325 cells/mm3 vs
480 cells/mm3). Almost a quarter had a history of a genital
ulcer in the last 3 months, and 2.9% had a genital ulcer present
upon entry into the study.
Over 5005 person-years of follow-up during the study, with a
median follow-up duration of 20 months (interquartile range
[IQR], 15–24 months), 752 genital ulcers were reported (213
in the acyclovir arm and 539 in the placebo arm). Of those le-
sions, swab specimens were collected from 622 (83%) and tested
for HSV-2 by PCR; 415 (67%) were positive, including 89 of 180
(49%) in the acyclovir arm and 326 of 442 (74%) in the placebo
arm.
During the follow up period, 349 HIV-infected study partic-
ipants initiated ART, with a median duration of follow-up of 10
months (IQR, 5–13 months). The incidence of genital ulcers in-
creased from 15.0 per 100 person-years prior to initiation of
ART to 26.9 per 100 person-years in the first full quarter after
initiation of ART (adjusted IRR, 1.83 [95% confidence interval
{CI}, 1.06–3.16]; P = .03; Table 2). For HSV-2–positive genital
ulcers, the rate increased from 8.1 per 100 person-years to
19.0 per 100 person-years (IRR, 2.20 [95% CI, 1.12–4.33];
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P = .02). Sensitivity analysis treating this outcome as missing for
episodes of GUD without HSV-2 PCR testing results yielded
similar rate ratio estimates (Supplementary Table 1). After the
first full quarter, the incidence of GUD and HSV-2–positive ul-
cers returned to values closer to pre-ART levels, although the
numbers were small. Sensitivity analyses that included the quar-
ter in which ART was initially reported, categorized as the first
quarter, yielded results that were not as strong, likely reflecting
increased misclassification of ART status for the additional in-
cluded quarters (IRR, 1.37 [95% CI, .89–2.10; P = .16] for GUD
and 1.65 [95% CI, .95–2.87; P = .08] for HSV-2–positive GUD).
The effect of acyclovir on HSV-2–positive genital ulcers is
shown graphically in Figure 1. We observed lower HSV-2–
associated GUD incidence in the acyclovir group, compared
with the placebo group, during each period; however, the pro-
nounced increase in GUD and HSV-2–positive GUD during
the first full quarter after the start of ART was noted whether
acyclovir or placebo was received (P = .25). An alternative anal-
ysis limited to only those individuals who ultimately started
ART for the “prior to ART initiation” calculation had wider
CIs but showed a similar increase in adjusted IRR (Supplemen-
tary Table 2).
To understand better whether the increased risk was associ-
ated with a brisk response to ART, we identified 252 persons
who had a documented increase in CD4+ T-cell count by at
least 50 cells/mm3 or a viral load decrease of at least 2 log10,
compared with the baseline measurement. In this group, the
median increase in CD4+ T-cell count was from 192 to 319
cells/mm3 and the decrease in plasma HIV RNA load was
from 5.01 to 2.08 log10 copies/mm
3 after a median of 6 months.
Their adjusted IRRs for GUD and HSV-2–positive GUD were
qualitatively similar to those from analysis of the overall popu-
lation (Supplementary Table 3).
DISCUSSION
We showed here that initiation of ART in HIV/HSV-2–
coinfected persons is associated with a transient increase in
the incidence of genital ulcers and specifically genital ulcers
caused by HSV-2. This increase in GUD is the primary clinical
manifestation of HSV-2–associated IRIS. We also showed that
acyclovir 400 mg twice daily reduces the incidence of genital ul-
cers overall but does not prevent an increase in GUD incidence
following initiation of ART. Although HSV is mentioned in
several reports about IRIS, most referred to GUD or clinically
diagnosed genital herpes [16–19], and many had variable fol-
low-up. With the exception of an early small case series [16],
ours is the first to document that most of the GUD observed
after initiation of ART was caused by HSV-2. It is likely that
some of the HSV-2–negative genital ulcers in our study were
caused by HSV-2, but viral shedding ceased by the time the
ulcer was swabbed, especially among acyclovir recipients.
The recent report by Tobian et al [20] is the best-documented
study to date of increased reactivation of HSV-2 after initiation
of ART. Their report was a secondary analysis from a study to
evaluate the impact of suppressive acyclovir therapy on progres-
sion of HIV disease [25]. In that study, 132 of 440 enrollees ini-
tiated ART and were followed for development of GUD. These
authors did not test the genital ulcers for HSV-2. This study
Table 1. Enrollment Characteristics of Participants Coinfected With Human Immunodeficiency Virus Type 1 (HIV) and Herpes Simplex Virus Type 2, by
Antiretroviral Therapy (ART) Status
Characteristic
Placebo (n=1688) Acyclovir (n=1693)
Not Started ART (n = 1498) Started ART (n = 190) Not Started ART (n = 1534) Started ART (n = 159)
Age, y 31.8 (26.4–38.0) 34.0 (28.5–42.3) 32.0 (26.9–37.9) 33.7 (29.0–41.0)
Female sexa 69 61 67 62
Plasma HIV load, log10 copies/mL 3.99 (3.30–4.58) 4.65 (3.91–5.12) 4.04 (3.33–4.61) 4.68 (4.01–5.18)
CD4+ T-cell count, cells/mm3 478 (361–647) 324 (286–402) 486 (367–660) 325 (280–416)
History of GUD in last 3 months 328 (21.9) 48 (25.3) 347 (22.6) 40 (25.2)
GUD present on entry examination 37 (2.5) 10 (5.3) 46 (3.0) 4 (2.5)
Pathogen
T. pallidumb 94 (6.3) 10 (5.3) 92 (6.0) 4 (2.5)
C. trachomatisc 33 (2.4) 2 (1.1) 33 (2.3) 0
N. gonorrhoeaec 18 (1.3) 1 (0.6) 29 (2.0) 1 (0.7)
T. vaginalisc 191 (13.7) 15 (8.2) 193 (13.3) 17 (11.0)
Any of the aboved 296 (21.3) 24 (13.1) 300 (20.6) 19 (12.3)
Data are median value (interquartile range) or no. (%) of subjects.
Abbreviation: GUD, genital ulcer disease.
a The numbers in this row are percentages.
b Serological testing for Treponema pallidumwas performed at all sites, using rapid plasma reagin, with confirmation by themicrohemagglutination test for T. pallidum at sites with that capacity.
c Batch testing for Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis was performed on archived cervical and urine samples at the University of Washington.
d Denominator for this calculation excludes 195 participants who had no laboratory results available.
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found that the adjusted prevalence rate ratio of GUDwas 1.94 in
the 3 months following ART initiation. The magnitude of this
change is similar to the IRR that we found for GUD after initi-
ating ART (1.83) in our larger cohort, although the results can-
not be directly compared. The 96 female subjects in the study of
Tobian et al [20] who initiated ART provided monthly vaginal
swabs that were tested for HSV-2 DNA, enabling evaluation of
genital HSV-2 shedding before and after ART. The impact on
viral shedding was also significant, with an odds ratio of 2.83
at month 1, 2.84 at month 2, and 3.15 at month 3 (all calculated
using the 6 months prior to ART initiation as a reference). Viral
shedding returned to baseline at month 4 and beyond. Our
study design did not allow us to measure viral shedding in
this same way, so we were unable to confirm this observation.
Acyclovir remains a useful drug, but its efficacy may be
blunted in persons coinfected with HIV and HSV-2. Although
it significantly reduced the incidence of GUD in our study, it
did not improve the IRR following initiation of ART. The report
by Tobian et al had comparable rates in their acyclovir and
placebo arms [20]. In a separate analysis from this same cohort,
we also showed that acyclovir suppression did not reduce trans-
mission of HSV-2 to susceptible partners [26].However, anoth-
er analysis from this cohort showed that acyclovir suppression
reduced the incidence of herpes zoster [27]. These observations
confirm acyclovir’s usefulness but suggest that more-potent an-
tiherpes drugs are needed.
One of the limitations of our study is the relatively short pe-
riod of observation following initiation of ART. This limits the
precision with which we can estimate the duration of the in-
creased incidence of GUD following initiation of ART. Howev-
er, our estimate of ≥3 months (the first full quarter) is similar toTa
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Figure 1. Incidence of herpes simplex virus type 2 (HSV-2)–specific ulcers, strat-
ified by randomization treatment group and time since antiretroviral therapy (ART)
initiation. The incidence rate ratio (IRR) for HSV-2 ulcers was calculated by compar-
ing acyclovir versus placebo in the respective strata of time from ART initiation. The
pre-ART group is based on the entire study population, whereas the 2 subsequent
groups are based only on the 349 individuals who initiated ART. Incidence rates in
the figure are as reported for HSV-2–positive genital ulcer disease in Table 2. Ab-
breviation: CI, confidence interval.
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that identified in other studies [20]. Because we asked about an-
tiretroviral initiation only at quarterly visits, the estimate of the
time of initiation was imprecise. By excluding the quarter in
which ARTwas initiated from the analysis, we may have exclud-
ed up to nearly 3 months of postinitiation observation for some
individuals. Similarly, because we only asked about genital ul-
cers at quarterly visits, some episodes of GUD may have gone
unreported. This limitation was partially abated by recording
spontaneous reports of genital ulcers and swabbing them at
monthly visits, but because routine examinations were not
done at monthly visits, some episodes may still have been
missed.
In summary, initiation of ART in HIV/HSV-2–coinfected
persons doubles the incidence of GUD and HSV-2–associated
GUD in the first 3 months. This impact is not eliminated by
suppressive acyclovir therapy, although the incidence of GUD
is reduced. Clinicians should consider acyclovir suppression
around the time of ART initiation, especially in persons with
a history of symptomatic GUD, in order to blunt the anticipated
increase in GUD incidence. This recommendation is also con-
sistent with the current opportunistic infection treatment
guidelines [28].
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